Loading...
•
Jun 30, 2021
Adaptimmune Q2 2021 Earnings Report
Reported financial results and provided a business update.
Key Takeaways
Adaptimmune reported financial results for the second quarter ended June 30, 2021. The company had cash and cash equivalents of $50.5 million and Total Liquidity of $285.4 million. Revenue for the quarter was $3.1 million, and the company believes its existing funds will support operations into early 2023.
SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year.
SURPASS trial data from 23 evaluable patients to be presented at ESMO.
ADP-A2AFP Phase 1 trial data from 11 evaluable patients in Group 3/Expansion to be presented at ILCA.
Financial guidance confirmed: funded into early 2023.
Forward Guidance
The Company believes that its existing cash, cash equivalents and marketable securities will fund the Company’s current operations into early 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...